Los Angeles Capital Management’s Ultragenyx Pharmaceutical RARE Stock Holding History

Los Angeles Capital Management’s Portfolio RARE Stock Details RARE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$11.8K	Hold	353	–	–	﹤0.01%	1922
2026 Q1	$7.39K	Sell	353 -134,114	-100%	-$3.02M	﹤0.01%	2015
2025 Q4	$4.73M	Sell	134,467 -60,515	-31%	-$1.99M	0.02%	315
2025 Q3	$5.87M	Buy	+194,982	New	+$5.85M	0.02%	319
2022 Q1	–	Sell	-5,169	Closed	-$435K	–	1479
2021 Q4	$435K	Sell	5,169 -1,949	-27%	-$159K	﹤0.01%	1072
2021 Q3	$642K	Hold	7,118	–	–	﹤0.01%	948
2021 Q2	$679K	Sell	7,118 -2,886	-29%	-$301K	﹤0.01%	1028
2021 Q1	$1.14M	Sell	10,004 -8,777	-47%	-$1.19M	0.01%	837
2020 Q4	$2.6M	Buy	18,781 +101	+0.5%	+$12K	0.01%	578
2020 Q3	$1.53M	Buy	18,680 +3,360	+22%	+$279K	0.01%	656
2020 Q2	$1.2M	Buy	15,320 +2,260	+17%	+$150K	0.01%	785
2020 Q1	$580K	Buy	+13,060	New	+$678K	﹤0.01%	858
2019 Q4	–	Sell	-5,780	Closed	-$247K	–	1332
2019 Q3	$247K	Hold	5,780	–	–	﹤0.01%	1168
2019 Q2	$367K	Sell	5,780 -10,540	-65%	-$671K	﹤0.01%	1124
2019 Q1	$1.13M	Sell	16,320 -1,000	-6%	-$57.1K	0.01%	813
2018 Q4	$753K	Buy	17,320 +1,515	+10%	+$82.8K	﹤0.01%	836
2018 Q3	$1.21M	Buy	15,805 +1,440	+10%	+$117K	0.01%	803
2018 Q2	$1.1M	Sell	14,365 -380	-3%	-$24.5K	0.01%	859
2018 Q1	$752K	Buy	+14,745	New	+$743K	﹤0.01%	910

Other funds holding RARE

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Sands Capital Management Arlington, Virginia $26.9B AUM 34.44% 1-Year Est. Return

Jacobs Levy Equity Management Florham Park, New Jersey $27.8B AUM 46.46% 1-Year Est. Return

FCM

Frontier Capital Management Boston, Massachusetts $10.7B AUM 67.78% 1-Year Est. Return

Los Angeles Capital Management's RARE Position: Q2 2026 in Review

Los Angeles Capital Management held its Ultragenyx Pharmaceutical (RARE) position steady in Q2 2026 at 353 shares worth $11.8K. The position accounts for ﹤0.01% of the portfolio, ranked #1922.

Los Angeles Capital Management first reported a position in RARE in Q1 2018 and has held it in 19 quarters since. The position peaked at $5.87M in Q3 2025. 311 funds tracked by Wall St. Rank hold RARE as of Q2 2026.

Los Angeles Capital Management held 353 shares of Ultragenyx Pharmaceutical worth $11.8K as of Q2 2026.
Los Angeles Capital Management left its Ultragenyx Pharmaceutical share count unchanged in Q2 2026.
Ultragenyx Pharmaceutical made up ﹤0.01% of Los Angeles Capital Management's portfolio in Q2 2026, its #1922 holding.
Los Angeles Capital Management first reported a position in Ultragenyx Pharmaceutical in Q1 2018 and has held it in 19 quarters since.
Los Angeles Capital Management's Ultragenyx Pharmaceutical position peaked at $5.87M in Q3 2025.
311 funds tracked by Wall St. Rank held Ultragenyx Pharmaceutical as of Q2 2026.

Based on Los Angeles Capital Management's 13F filing for Q2 2026, filed 13 Aug 2026.